Darwin Wealth Management’s BridgeBio Pharma BBIO Stock Holding History

Darwin Wealth Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$460	Buy	+7	New	+$545	﹤0.01%	1054

Other funds holding BBIO

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Laurion Capital Management New York $6.21B AUM 32.28% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $144B AUM 22.91% 1-Year Est. Return

GW&K Investment Management Boston, Massachusetts $11.8B AUM 29.45% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Darwin Wealth Management's BBIO Position: Q3 2026 in Review

Darwin Wealth Management opened a new position in BridgeBio Pharma (BBIO) in Q3 2026: 7 shares worth $460. The stake represents ﹤0.01% of the portfolio and ranks #1054 among its holdings.

233 funds tracked by Wall St. Rank hold BBIO as of Q3 2026.

Darwin Wealth Management held 7 shares of BridgeBio Pharma worth $460 as of Q3 2026.
BridgeBio Pharma was a new Darwin Wealth Management position in Q3 2026.
BridgeBio Pharma made up ﹤0.01% of Darwin Wealth Management's portfolio in Q3 2026, its #1054 holding.
233 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2026.

Based on Darwin Wealth Management's 13F filing for Q3 2026, filed 9 Nov 2026.